ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Comparison of the efficacy and clinical applications of three different myopia control methods: repeated low-level red light, 1% atropine, and orthokeratology lenses in children and adolescent.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, the mainstream methods for myopia control include atropine, orthokeratology lenses(OK lens), and repeated low-level red light (RLRL). In-depth exploration of different intervention methods are of great significance.
methods600 participants aged 8-16 years with a spherical equivalent (SE) of - 0.50 to - 7.50 D (D) completed 8 months treatment. They were divided into four groups: the RLRL, 1% atropine, OK lens and control (single-vision spectacles [SVS]) group. Each group comprised 150 patients .
resultsAt baseline, the difference was not statistically significant in the AL of the RLRL, 1% atropine, OK, and SVS groups (P > 0.05); After 8 months, significant differences were observed between the OK group and the RLRL, 1% atropine, SVS groups (P < 0.05). However, no statistically significant difference was found between the RLRL and 1% atropine groups. In the RLRL group, the difference in axial length (AL) progression between low myopia(LM) and high myopia(HM) subgroups was statistically significant (P < 0.05). the corneal curvature KI and K2 were statistically nonsignificant before and after the intervention(P > 0.05).At baseline, the SEs were not significantly different (P > 0.05). After 8 months. the OK, RLRL, and 1% atropine groups showed statistically significant differences in SE compared to the SVS group (P < 0 0.05).
conclusionRLRL, 1% atropine, and OK lenses were effective in controlling AL and SE increase compared with SVS, with RLRL and 1% atropine exhibiting better outcomes than OK lenses. KEY MESSAGES: WHAT IS KNOWN: Repeated low-level red light (RLRL), 1% atropine, and OK lenses were effective in controlling AL and SE increase in children and adolescents, and RLRL therapy has emerged as a novel therapy for myopia control with unexpected efficacy in axial shortening. WHAT IS NEW: Comprehensively analyzed the effectiveness and safety of three different myopia control strategies. RLRL was effective at controlling myopia progression according to different myopia regions, the decreases in AL in the longer AL group were greater than those in the shorter group. At the same time, our study further demonstrates that the differential efficacy of three myopia intervention regimens in patients with low, moderate, and high myopia.
Indexed as
Identifiers
41212220What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.